Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours

Working to improve global cancer care access in low middle-income countries

Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes

War in Ukraine: Global cancer aid to support refugees

ASCO and WHO to collaborate on quality indicators for cancer facilities

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

Spotlight on global cancer control at ASCO 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients